This review provides a brief overview of preclinical and clinical studies focusing on novel therapeutic options concerning specific KRAS, CDK4/6 inhibitors, and combination of immune checkpoint inhibitors with chemo or molecular targeted agents for the treatment of pancreatic cancer. Here, KRAS is linked to pancreatic neoplasm.